Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy

A technology for radiation therapy, prostate cancer, applied in the direction of genomics, measurement devices, biological tests, etc., can solve problems such as different responses

Pending Publication Date: 2019-11-26
DECIPHER BIOSCI INC +1
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, stage-matched tumors grouped by histological or molecular subtype may respond differently to the same treatment regimen

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
  • Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
  • Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0250] Example 1: Development of a Gene Signature to Predict Postoperative Radiation Therapy Response in Prostate Cancer Patients.

[0251] DNA damage repair (DDR) genes and pathways are significantly associated with increased risk of metastatic progression (Evans et al., Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostateectomy for High-Risk Prostate, JAMA Oncol. 2016 Jan 7:1-10 ). To assess the use of DDR genes in radiation response signatures in prostate cancer patients before prostatectomy. A compilation of 1,800 genes from Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA)—which are associated with DNA damage and radiation responses and the human exome array platform—was collected to identify the most likely predictors of response to radiation therapy (RT) subset of responsive genes.

[0252] To develop a postoperative radiation therapy response signature, patients treated and untreated with RT within one year were matched 1:1 in the ...

Embodiment 2

[0257] Example 2: PORTOS predicts response to radiation therapy in prostate cancer patients.

[0258] In the matched training cohort, PORTOS was able to predict response to radiotherapy (RT), as evidenced by a significant interaction term (p Figure 1A ). Among patients with high scores (PORTOS>0), treated patients had better outcomes than untreated patients, with a 10-year metastatic rate of 5% in RT-treated patients and 63% in untreated patients (p Figure 1B with 2A ), while among patients with low scores (PORTOS Figure 1B with 2B ). These results indicate that PORTOS of the present invention can be used to predict the benefit of postoperative RT in patients with prostate cancer. These results also indicate that the methods of the present invention are useful in the treatment of prostate cancer. These results further demonstrate that the methods of the present invention can be used to predict response to postoperative radiation therapy and treat prostate cancer in subjec...

Embodiment 3

[0259] Example 3: PORTOS predicts response to radiation therapy in independent validation of the model

[0260] To validate the model independently, matched treated and untreated radiotherapy (RT) patient cohorts were designed using pooled cohorts from four clinical sites (MCII, THU, TJU, and DVA). These results were confirmed in independently matched validation cohorts with significant interaction terms (p Figure 1C ). Within the high PORTOS group, RT-treated patients had better outcomes than untreated patients (p=0.01, HR=0.19 [0.048-0.78], Figure 2C ), with a 10-year metastatic rate of 4% in RT-treated patients and 31% in untreated patients ( Figure 1D ). In the low PORTOS group, untreated patients had similar outcomes to treated patients (p=0.77, HR=0.92 [0.56-1.5], Figure 2D ), where the 10-year metastatic rate was 31% in RT-treated patients and 32% in untreated patients ( Figure 1D ).

[0261] These results provide further evidence that patients with high scores...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods, compositions, and kits for identifying individuals who will be responsive to post-operative radiation therapy for treatment of prostate cancer are disclosed. In particular, the invention relates to a genomic signature based on expression levels of DNA Damage Repair genes that can be used to identify individuals likely to benefit from post-operative radiation therapy after a prostatectomy.

Description

[0001] Cross References to Related Applications [0002] This application claims priority under 35 U.S.C. § 119(e) to U.S. Serial No. 62 / 379,178 filed August 24, 2016, the entire contents of which are hereby incorporated by reference in their entirety. technical field [0003] The present invention relates to the field of personalized medicine and methods for treating prostate cancer. In particular, the invention relates to the use of genomic signatures to identify individuals in need of treatment for prostate cancer who will respond to postoperative radiation therapy. Background technique [0004] Cancer is the uncontrolled growth of abnormal cells anywhere in the body. Abnormal cells are called cancer cells, malignant cells, or tumor cells. Many cancerous and abnormal cells that make up cancerous tissue are further identified by the name of the tissue from which the abnormal cells originate (eg, prostate cancer). Cancer cells can proliferate uncontrollably and form canc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/48G01N33/574C40B40/06G16B25/10G16B25/20
CPCC12Q2600/106C12Q2600/158G16B20/00G16B40/30G16B40/20G16B25/10C12Q1/6886Y02A90/10G16B25/20G01N33/574G01N33/48G16H50/30G16H50/20C12Q2600/118
Inventor E·达维西奥尼H·A·D·阿沙布N·埃尔霍S·G·赵S·L·常F·Y·冯
Owner DECIPHER BIOSCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com